Venetoclax-induced panniculitis in an acute myeloid leukemia patient
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04372-0
Abstract: Dear Editor, As a selective B cell leukemia/lymphoma-2 (BCL2) inhibitor, venetoclax, in combination with low-dose cytarabine (LDAC) [1] or hypomethylating agents [2], was approved for the treatment of intensive chemotherapy-ineligible acute myeloid leukemia (AML). Bone… read more here.
Keywords: induced panniculitis; venetoclax induced; panniculitis; treatment ... See more keywords